137 related articles for article (PubMed ID: 30479568)
1. Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma.
Wang R; Yang L; Jin S; Han X; Liu B
Cancer Cell Int; 2018; 18():189. PubMed ID: 30479568
[TBL] [Abstract][Full Text] [Related]
2. Effect of Thyroid-Stimulating Hormone Suppression Therapy on Cardiac Structure and Function in Patients With Differentiated Thyroid Cancer After Thyroidectomy: A Systematic Review and Meta-Analysis.
Zhang H; Yang Y; Gao C; Tian L
Endocr Pract; 2024 Feb; 30(2):177-186. PubMed ID: 38007181
[TBL] [Abstract][Full Text] [Related]
3. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
4. Measurements of Bone Health after Thyroid-Stimulating Suppression Therapy in Postmenopausal Women with Differentiated Thyroid Carcinoma: Bone Mineral Density versus the Trabecular Bone Score.
Chung CW; Choi HS; Kong SH; Park YJ; Park DJ; Ahn HY; Cho SW
J Clin Med; 2021 May; 10(9):. PubMed ID: 34063726
[TBL] [Abstract][Full Text] [Related]
5. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
Taillard V; Sardinoux M; Oudot C; Fesler P; Rugale C; Raingeard I; Renard E; Ribstein J; du Cailar G
Clin Endocrinol (Oxf); 2011 Nov; 75(5):709-14. PubMed ID: 21645022
[TBL] [Abstract][Full Text] [Related]
6. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
7. Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer.
Lee JC; Song BS; Kang YM; Kim YR; Kang YE; Lee JH; Shong M; Yi HS
Front Endocrinol (Lausanne); 2021; 12():769074. PubMed ID: 34858341
[TBL] [Abstract][Full Text] [Related]
8. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
9. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone therapy in differentiated thyroid cancer.
Grani G; Ramundo V; Verrienti A; Sponziello M; Durante C
Endocrine; 2019 Oct; 66(1):43-50. PubMed ID: 31617165
[TBL] [Abstract][Full Text] [Related]
11. Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis.
Won HR; Jeon E; Chang JW; Kang YE; Song K; Kim SW; Lim DM; Ha TK; Chung KW; Kim HJ; Park YJ; Koo BS
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326621
[TBL] [Abstract][Full Text] [Related]
12. Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma.
Zhang P; Xi H; Yan R
Onco Targets Ther; 2018; 11():6687-6692. PubMed ID: 30349302
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer.
Hong KS; Son JW; Ryu OH; Choi MG; Hong JY; Lee SJ
Int J Endocrinol; 2016; 2016():9846790. PubMed ID: 27418929
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Thyroid-Stimulating Hormone on Tumor Size in Differentiated Thyroid Carcinoma.
Ozemir IA; Gurbuz B; Bayraktar B; Aslan S; Başkent A; Yalman H; Yigitbasi R; Alimoglu O
Indian J Surg; 2015 Dec; 77(Suppl 3):967-70. PubMed ID: 27011492
[TBL] [Abstract][Full Text] [Related]
16. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
[TBL] [Abstract][Full Text] [Related]
17. Thyroid function and left ventricular structure and function in the Framingham Heart Study.
Pearce EN; Yang Q; Benjamin EJ; Aragam J; Vasan RS
Thyroid; 2010 Apr; 20(4):369-73. PubMed ID: 20210671
[TBL] [Abstract][Full Text] [Related]
18. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
19. Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer.
Zhang X; Zhang X; Chang Z; Wu C; Guo H
J BUON; 2018; 23(5):1467-1471. PubMed ID: 30570874
[TBL] [Abstract][Full Text] [Related]
20. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
